Role of endorectal MR imaging and MR spectroscopic imaging in defining treatable intraprostatic tumor foci in prostate cancer: Quantitative analysis of imaging contour compared to whole-mount histopathology

Abstract

Purpose To investigate the role of endorectal MR imaging and MR spectroscopic imaging in defining the contour of treatable intraprostatic tumor foci in prostate cancer, since targeted therapy requires accurate target volume definition. Materials and Methods We retrospectively identified 20 patients with prostate cancer who underwent endorectal MR imaging and MR spectroscopic imaging prior to radical prostatectomy and subsequent creation of detailed histopathological tumor maps from whole-mount step sections. Two experienced radiologists independently reviewed all MR images and electronically contoured all suspected treatable (≥ 0.5 cm3) tumor foci. Deformable co-registration in MATLAB was used to calculate the margin of error between imaging and histopathological contours at both capsular and non-capsular surfaces and the treatment margin required to ensure at least 95% tumor coverage. Results Histopathology showed 17 treatable tumor foci in 16 patients, of which 8 were correctly identified by both readers and an additional 2 were correctly identified by reader 2. For all correctly identified lesions, both readers accurately identified that tumor contacted the prostatic capsule, with no error in contour identification. On the non-capsular border, the median distance between the imaging and histopathological contour was 1.4 mm (range, 0 to 12). Expanding the contour by 5 mm at the non-capsular margin included 95% of tumor volume not initially covered within the MR contour. Conclusions Endorectal MR imaging and MR spectroscopic imaging can be used to accurately contour treatable intraprostatic tumor foci; adequate tumor coverage is achieved by expanding the treatment contour at the non-capsular margin by 5 mm.

Prostate tumor delineation using multiparametric magnetic resonance imaging: Inter-observer variability and pathology validation

“…22 MR sequences was not studied by these authors. Anwar et al compared delineations by two observers on T2w imaging and MR spectroscopy with delineations on histology and found these to differ by a median distance of 1.4 mm [14].…”

From whole gland to hemigland to ultra-focal high-dose-rate prostate brachytherapy: A dosimetric analysis

“…The average diameter of target lesions in low-and intermediate-risk patients was 1.4 and 1.5 cm, corresponding to treatment volumes of 1.4 and 1.8 cm 3 . Recent work comparing imaging-defined lesions to pathologic specimens demonstrates that a 5 mm margin on imaging-defined lesions covers 95% of the tumor volume that is missed on the imaging-defined capsular border alone (10). Adding a 5 mm margin to the MRI-defined lesions results in mean treatment volumes of 3.5 and 4.3 cm 3 for lowand intermediate-risk groups.…”

Genitourinary Applications of MR-Guided High-Intensity Focused Ultrasound

“…A recent study of patients undergoing endorectal multiparametric MRI prior to radical prostatectomy (n = 88) demonstrated that all T2-weighted tumor targets were correctly identified dominant tumor foci when associated with at least 0.54 cm 3 of concordant spectroscopic imaging abnormality [58]. A subsequent study (n = 20) employing this definition of target tumor showed that all 9 tumor foci independently identified by both readers were correctly identified dominant tumor sites, but 5 lesions identified by only one reader were all false positives [67]. This suggests that identification of treatable tumor foci prior to MR-guided HIFU for prostate cancer should require both multiparametric and independent multi-reader confirmation.…”

“…A study utilizing multiparametric MRI data and quantitative analysis of imaging contour compared to whole-mount histopathology adequate tumor coverage is achieved by expanding the treatment contour at the non-capsular margin by 5 mm, with no expansion required at the capsular margin [67].…”